<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03248479</url>
  </required_header>
  <id_info>
    <org_study_id>5F9005</org_study_id>
    <nct_id>NCT03248479</nct_id>
  </id_info>
  <brief_title>Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination With Azacitidine in Patients With Hematological Malignancies</brief_title>
  <official_title>A Phase 1b Trial of Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination With Azacitidine in Patients With Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Forty Seven, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Forty Seven, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will evaluate Hu5F9-G4, a monoclonal antibody which is designed to block a protein
      called CD47, which is widely expressed on human cancer cells. Blocking CD47 with Hu5F9-G4 may
      enable the body's immune system to find and destroy the cancer cells. In this study, Hu5F9-G4
      may be given alone or in combination with azacitidine to patients with acute myeloid leukemia
      (AML) or higher risk myelodysplastic syndrome (MDS). Azacitidine is a drug used for treatment
      of AML or MDS in patients who are not eligible for typical chemotherapy.

      The major aims of the study are: to confirm the safety and tolerability of Hu5F9-G4
      monotherapy in a relapsed/refractory AML and MDS population, and of Hu5F9-G4 in combination
      with azacitidine in previously untreated AML and MDS; and to evaluate the efficacy of
      Hu5F9-G4 monotherapy in relapsed/refractory AML/MDS, and of Hu5F9-G4 in combination with
      azacitidine in previously untreated AML/MDS, as measured by the objective response rate.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 12, 2017</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>28 days</time_frame>
    <description>Adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 or customized AE severity grading as defined in the protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>Objective Response Rate as defined by the Investigator according to protocol-specified criteria based on European LeukemiaNet (ELN) AML recommendations (Döhner 2017), International Working Group (IWG) AML response criteria (Cheson 2003), or IWG MDS response criteria (Cheson 2006) where appropriate</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Relapsed/Refractory AML or MDS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with relapsed or refractory AML or intermediate/high risk MDS will receive Hu5F9-G4 monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment-naive Unfit AML or MDS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with previously untreated AML who are ineligible for standard induction chemotherapy, or previously untreated intermediate/high risk MDS, will receive Hu5F9-G4 in combination with azacitidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rollover</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients on a previous AML Phase 1 trial (SCI-CD47-002) with clinical benefit on Hu5F9-G4 treatment will receive Hu5F9-G4 monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hu5F9-G4</intervention_name>
    <description>Hu5F9-G4 will be administered up to twice weekly.</description>
    <arm_group_label>Relapsed/Refractory AML or MDS</arm_group_label>
    <arm_group_label>Treatment-naive Unfit AML or MDS</arm_group_label>
    <arm_group_label>Rollover</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Azacitidine will be administered daily for 7 days in each 28-day cycle.</description>
    <arm_group_label>Treatment-naive Unfit AML or MDS</arm_group_label>
    <other_name>VIDAZA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets the criteria below for the appropriate cohort:

               1. Relapsed/Refractory Cohorts: Pathologically confirmed relapsed or refractory
                  (primary refractory and/or relapsed refractory) AML or confirmed intermediate,
                  high, or very high risk MDS that is relapsed, refractory or intolerant to
                  conventional therapy

               2. Treatment-naïve/ Unfit Cohorts: Previously untreated patients with histological
                  confirmation of AML who are ineligible for treatment with a standard cytarabine
                  and anthracycline induction regimen; or previously untreated patients with
                  intermediate, high, or very high risk MDS. Prior and concurrent therapy with
                  hydroxyurea, oral etoposide, erythroid and/or myeloid growth factors is allowed.

               3. Rollover Cohort: Patients on active Hu5F9-G4 therapy on the Phase 1 AML
                  (SCI-CD47-002) trial who are deriving clinical benefit by Investigator assessment

          -  White blood cell (WBC) count ≤ 20 x 10E3/µL

          -  Adequate performance status and hematological, liver, and kidney function

        Exclusion Criteria:

          -  Prior treatment with CD47 or signal regulatory protein alpha (SIRPα) targeting agents
             (with exception of Hu5F9-G4 for patients in the Rollover cohort).

          -  Treatment-naïve/Unfit Cohorts Only: Any prior anti-leukemic therapy (excluding
             hydroxyurea or oral etoposide), prior treatment with hypomethylating agents and/or low
             dose cytarabine.

          -  Acute promyelocytic leukemia.

          -  Known inherited or acquired bleeding disorders.

          -  Previous allogeneic hematopoietic stem cell transplant within 6 months prior to
             enrollment, active graft versus host disease (GVHD), or requiring transplant-related
             immunosuppression.

          -  Clinical suspicion of active central nervous system (CNS) involvement by leukemia

          -  Known active or chronic hepatitis B or C infection or HIV

          -  Pregnancy or active breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Chao, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Forty Seven, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark Chao, MD PhD</last_name>
    <phone>1-650-352-4150</phone>
    <email>medical@fortyseveninc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chris Takimoto, MD PhD</last_name>
    <phone>1-650-352-4150</phone>
    <email>medical@fortyseveninc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Guido Marcucci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Daniel Pollyea</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Sallman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Medical Center (HCA Midwest Health)</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Suman Kambhampati</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mark Frattini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology Centennial Clinic (Sarah Cannon Research Institute)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>William Donnellan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Naval Daver</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital, Oxford University</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Paresh Vyas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2017</study_first_submitted>
  <study_first_submitted_qc>August 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2017</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hu5F9-G4</keyword>
  <keyword>CD47</keyword>
  <keyword>azacitidine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

